Overall, our study identifies, for the first time, c-JUN as a targetable mechanism of adaptive resistance to BRAF inhibition in BRAFV600E CRC paving the way to the development of future combinational therapeutic strategies incorporating JNKi. Here, BRAF is linked to colorectal carcinoma.